Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut de cancérologie Strasbourg Europe
With
UR 3072 - Mitochondrie, Stress oxydant et Protection musculaire
All subjects will be evaluated a single time during two hours. For patients from group 1 the evaluation should take place within the two weeks that follow the end of adjuvant treatment. There is no specificity regarding evaluation of volunteers from group 2, their evaluation can take place at any time.
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Group 1 - Patients :
Give written inform consent
Age ≥ 18 years
Affiliate to social security system
Ability to speak, understand and read French
Breast cancer, Stage II or III, treated by taxane-based chemotherapy
Group 2 - Control group :
Give written inform consent
Age ≥ 18 years
Affiliate to social security system
Ability to speak, understand and read French
You may not be if
Group 1 - Patients :
\< 18 years old or patients ≥ 18 years old under guardianship, or supervision
Psychiatric, musculoskeletal or neurologic disorders
Patients presenting one of the following contraindications to transcranial magnetic stimulation :
Presence of a implanted metallic foreign-body (cochlear implant, drug pump system, pacemaker, etc.)
History of epilepsy
Brain injury (vascular, traumatic, tumour-induced, infectious or metabolic)
Women that are pregnant
Serious or recent heart disease
Group 2 -Control group :
\< 18 years old or patients ≥ 18 years old under guardianship, or supervision
Psychiatric, musculoskeletal or neurologic disorders
Pacemaker implantation
History of cancer
All known chronic disease
Subjects presenting one of the following contraindications to transcranial magnetic stimulation :
Presence of a implanted metallic foreign-body (cochlear implant, drug pump system, pacemaker, etc.)
History of epilepsy
Brain injury (vascular, traumatic, tumour-induced, infectious or metabolic)
Women that are pregnant
Serious or recent heart disease
Clareo Health | Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy (PROTECT-04)
